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Introduction
Cardiovascular diseases, such as myocardial infarction, stroke, 
and deep vein thrombosis, are leading causes of death and dis-
ability. These potentially occlusive processes are influenced in part 
by platelet secretion (1, 2). As a physiological response to vascular 
damage, platelets are activated and secrete components that pro-
mote thrombus formation and initiate its sequelae, e.g., wound 
healing and angiogenesis (1, 3, 4). Platelet secretion is mediated by 
highly conserved soluble N-ethylmaleimide–sensitive factor (NSF) 
attachment protein receptor (SNARE) proteins: vesicle/granule 
SNAREs (v-SNAREs) consist of the vesicle-associated membrane 
proteins (VAMPs), and target membrane SNAREs (t-SNAREs) 
consist of 2 classes, syntaxins and members of the synaptosomal-
associated protein 23/25 (SNAP23/25) family. A trans-membrane 
complex of these 3 proteins mediates bilayer fusion and thus 
granule cargo release (5). In human and mouse platelets, this 
core fusion complex includes VAMP8, SNAP23, and syntaxin-11 
(STX11) (6–9). These core elements are acted on by regulatory 
proteins, which affect when and where SNARE interactions occur. 
This assures physiologically relevant secretion (10, 11). In platelets, 
syntaxin regulators such as Munc18b and tethering proteins such 
as Munc13-4 and Rab27 are required for granule release (1, 12, 13). 
Genome-wide association studies (GWAS) have linked other secre-
tory regulators to cardiovascular diseases (14–20); thus, to under-
stand the significance of these associations, it is important to deter-
mine which types of SNARE regulators control platelet secretion.
In our continuing effort to identify new secretion regulators, we 
used t-SNARE–containing complexes to capture SNARE-binding 
proteins from platelet extracts. We identified syntaxin-binding pro-
tein 5 (STXBP5; also known as tomosyn-1 [i.e., “friend of syntax-
in”]) as a novel candidate for affecting platelet secretion. STXBP5 is 
a 130-kDa protein that was originally identified as a STX1-binding 
partner in neuronal tissue (21). Subsequent studies have shown 
that STXBP5 interacts with other syntaxin isoforms and is widely 
expressed (22). STXBP5 belongs to a family of WD40 repeat–con-
taining proteins associated with exocytosis and with the actin cyto-
skeleton: Sro7/Sro77 in yeast, Tom1 in C. elegans, and STXBP5 in 
mammals (23–28). In mammals, 2 genes are present, Stxbp5 and 
Stxbp5l (also known as Tomosyn-2), and alternative splicing pro-
duces 7 protein isoforms (29, 30). STXBP5 has 3 isoforms, based on 
molecular weight: big, middle, and small (b-STXBP5, m-STXBP5, 
and s-STXBP5, respectively). Structurally, STXBP5 is composed of 
an N-terminal WD40 repeat (~90% of the total protein sequence), 
a highly variable linker region, and a C-terminal v-SNARE (or 
R-SNARE) motif (30). The v-SNARE motif is proposed to exert a 
negative effect on fusogenic SNARE complex assembly by blocking 
v-SNARE binding to t-SNAREs (31). Consistently, overexpression 
of STXBP5 in neurons and neuroendocrine secretory cells inhib-
its exocytosis, and gene mutations in C. elegans or genetic deple-
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STX4 were used as surrogates to create syntaxin-SNAP23 and 
syntaxin-Munc18 complexes for pulldown assays. Using human 
platelet extracts and various syntaxin-containing complexes as 
bait, we recovered 5 bands that represented proteins specifically 
bound to 1 or more of the syntaxin-containing baits used (Figure 
1A). Mass spectrometry analysis showed that bands T1 and T2 
were STXBP5, band T3 was phosphofructokinase C, band T4 was 
Munc18b, and band T5 was granuphilin (also known as SLP4) (Fig-
ure 1 and Supplemental Table 1; supplemental material available 
online with this article; doi:10.1172/JCI75572DS1). Munc18b is 
known to be required for platelet secretion and to bind to t-SNARE 
complexes (13, 37). Granuphilin is a known Rab27 effector and is 
important for dense granule secretion (12, 38). The role of phos-
phofructokinase is unclear at present. STXBP5 has been shown to 
be involved in neuronal and neuroendocrine exocytosis (21, 24, 
39). Platelet STXBP5 (bands T1 and T2) was specifically associ-
ated with t-SNARE heterodimers, consistent with previous reports 
showing that STXBP5 forms ternary complexes with STX4/
SNAP23 and STX1/SNAP25 (22, 31). To verify STXBP5 expression 
in human platelets and our mass spectrometry results, we probed 
platelet extracts and affinity-purified complexes by IB using an 
anti-STXBP5 peptide mAb (whose epitope is a region shared by 
all 3 isoforms). A specific immunoreactive band was only seen in 
samples bound to the t-SNARE heterodimers, not in those bound 
to Munc18a- or Munc18c-containing complexes (Figure 1B). 
To determine which STXBP5 isoforms were present in human 
platelets, RT-PCR analysis was performed using random hexam-
ers and oligo d(T) to prime the reverse transcription step, then 
using isoform-specific primers for PCR (29, 40). Only primers for 
m-STXBP5 produced a product (Figure 1C), which suggests that 
m-STXBP5 is the most abundant isoform in platelets. Expression 
of STXBP5 has been consistently reported previously, in the mass 
spectrometry analysis of the human platelet proteome by Burkhart 
et al. (41) and in a genome-wide RNA sequence analysis of human 
and mouse platelets by Rowley et al. (42).
tion of Stxbp5 in mice enhances synaptic transmission (24, 32, 33). 
However, the N-terminal domain of STXBP5, lacking the syntaxin- 
binding v-SNARE motif, can also inhibit secretion from PC-12 cells, 
which suggests that other interactions with STXBP5 are important 
(33). Conversely, knockdown of STXBP5 in superior cervical gan-
glion neurons (34) and in the rat β cell line INS-1E (35), and genetic 
depletion of the homologs Sro7 and Sro77 in yeast (25), negatively 
affects exocytosis. Thus, although STXBP5 may be a negative regu-
lator of secretion in some cells, it may play a positive role in others 
(24). To date, the role of this potential SNARE regulator in platelets 
has not been addressed.
Various studies have linked STXBP5 with neuropsychological 
and cardiovascular diseases in humans. Deletions in the Stxbp5 
gene are linked to autism (36). GWAS show genetic variations in 
Stxbp5 are linked with increased plasma levels of vWF (14–19), 
alterations in tissue plasminogen activator (tPA) levels (20), 
venous thrombosis (16), and arterial thrombosis (19). Specifically, 
1 SNP that produces a nonsynonymous mutation (N436S) was 
associated with increased bleeding (18). These associations sug-
gest a role for STXBP5 in both endothelial cell (EC) and platelet 
secretion and point to a role for the protein in normal hemostasis. 
In the present study, we examined the platelet phenotype of mice 
lacking STXBP5 to understand how this t-SNARE regulator affects 
platelet exocytosis, granule biogenesis, and hemostasis.
Results
STXBP5 is present in human platelets. The critical SNAREs in plate-
lets have been identified: STX11 and SNAP23 as the t-SNAREs, 
and VAMP8 as the primary v-SNARE (6, 8, 9). Of these 3 SNARE 
types, syntaxins and their binding proteins have dominated the 
ranks of potential secretion regulators, which suggests that syn-
taxins or syntaxin-containing complexes might serve as useful 
“bait” to identify additional secretion regulators. Because of our 
problems with the insolubility of STX11 when expressed in bac-
teria (S. Ye and J. Zhang, unpublished observation), STX2 and 
Figure 1. STXBP5 is present in human platelets. (A) The indicated com-
plexes were produced in E. coli using the pRSFDuet plasmid with the S-tag 
peptide fused to the C terminus of the syntaxin. Complexes were bound 
to protein S agarose beads. After washing, the complex-bound beads were 
incubated with solubilized human platelet extracts (Plt. ext.). The beads 
were washed again, and the proteins were eluted with SDS-PAGE loading 
buffer. The eluted proteins were separated by SDS-PAGE and stained with 
Sypro Ruby. The specific interacting proteins (T1–T5) were excised, sub-
jected to trypsin digestion, and analyzed by mass spectrometry. The spec-
tra were searched using MASCOT software (see Supplemental Table 1 for 
search results). (B) The indicated complexes were produced in E. coli using 
the pRSFDuet plasmid with the S-tag peptide fused to the C terminus of 
the syntaxin. Solubilized human platelet extracts were incubated with the 
different complexes, and the resulting material was recovered on protein 
S agarose beads. After washing, the proteins were eluted and probed with 
anti-STXBP5 mAb. (C) Analysis of STXBP5 isoforms by RT-PCR. The human 
platelet–derived mRNA was converted to cDNA and preamplified by using 
either random hexamers or oligo d(T)16 primers, followed by regular PCR 
using isoform-specific primers for s-STXBP5, m-STXBP5, and b-STXBP5 
(see Methods). The 1-kb DNA ladder standard is at the far left.
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less, these data showed that STXBP5 associated with the critical 
secretory components SNAP23, STX11, and Munc18b in platelets 
and that its association was exclusive of the VAMPs.
STXBP5 localization in platelets. We next sought to deter-
mine the distribution of STXBP5 in platelets using biochemical 
fractionation and immunofluorescence microscopy. Resting and 
thrombin-activated platelets were disrupted by repeated freeze-
thaw and separated into cytosolic and pelleted fractions by cen-
trifugation (Figure 2E). The pelleted fractions were extracted 
sequentially with Triton X-100 and n-octyl-β-d-glucopyranoside 
to solubilize membrane proteins and lipid raft components, 
respectively. The cytosolic marker RabGDI fractionated into the 
first supernatant, and the membrane protein marker STX4 was 
found in the Triton X-100–solubilized fraction. The raft marker 
SNAP23 was present both in the Triton X-100–solubilized frac-
tion and in the n-octyl-β-d-glucopyranoside–solubilized fraction. 
STXBP5 was found in the final cytoskeletal pellet, consistent 
with actin’s presence (43). The distribution of STXBP5 in plate-
lets (spread on fibrinogen-coated coverslips) was also sugges-
tive of interaction with the cytoskeleton. STXBP5 was concen-
trated in the central region of the platelets and was surrounded 
by phalloidin-stained actin filaments (Figure 3, A–D). Because 
these platelets were surface-activated by spreading on coated 
glass, few granules remained, but P-selectin staining did appear 
in the central area of some platelets (Figure 3, A–D), consistent 
STXBP5 is associated with platelet SNARE machinery. To dem-
onstrate that STXBP5 does interact with the functionally rel-
evant syntaxin isoform in platelets, STX11 (as well as SNAP23 
and VAMP8), we immunoprecipitated endogenous STXBP5 
from detergent-solubilized extracts and probed the precipitate 
with antibodies against known elements of the platelet secretory 
machinery. Both resting and thrombin-stimulated human platelets 
were lysed with Triton X-100, and immunoprecipitation was per-
formed using nonspecific IgG or an anti-STXBP5 mAb. It should 
be noted that much of the platelets STXBP5 was in the pellet frac-
tion under these conditions; however, we chose to focus only on 
the soluble pool, so as to lessen the chance of detecting artifac-
tual interactions due to incomplete solubilization. IB showed that 
the t-SNAREs STX11 and SNAP23 were recovered in the STXBP5 
immunoprecipitates (Figure 2, A and B). Reciprocal immunopre-
cipitation with anti-STX11 antibodies confirmed this interaction 
(Figure 2C). In agreement with the in vitro pulldown results (Fig-
ure 1A), endogenous STXBP5 could also bind STX2 and STX4. No 
VAMP3 or VAMP8 was detected, consistent with the notion that 
STXBP5 competes with v-SNAREs to bind t-SNARE complexes 
(31). Another platelet secretory component, Munc18b, was coim-
munoprecipitated with STXBP5 (Figure 2B). Reciprocal immuno-
precipitation confirmed the STXBP5/Munc18b interaction (Figure 
2D). At this stage, it was not mechanistically clear why the com-
plex composition was unaffected by platelet activation. Regard-
Figure 2. STXBP5 is associated with platelet SNARE complexes and cytoskeleton. (A–D) Platelet extracts (Input) from resting (R) or thrombin-stimulated 
(S) platelets were prepared by solubilization with 1% Triton X-100. After clarification, platelet extracts were incubated with anti-STXBP5 mAb (A) or rabbit 
polyclonal Ab (B and D), anti-STX11 rabbit polyclonal Ab (C), anti-Munc18b goat polyclonal Ab (D), or IgG control for 3 hours at 4°C. Immune complexes were 
recovered with protein A and G sepharose. The bound proteins were eluted and separated by SDS-PAGE, followed by IB with the indicated antibodies.  
(E) Washed platelets (2.5 × 108) were resuspended in HEPES/Tyrode buffer and incubated with (stimulated) or without (resting) 0.1 U/ml thrombin for  
5 minutes. After disruption by freeze-thaw, the unbroken cells were removed by centrifugation at 700 g for 5 minutes, and supernatants were subjected to 
ultracentrifugation (100,000 g for 1 hour at 4°C). The cytosolic fractions (S1) were collected. The remaining pellets were solubilized sequentially with Triton 
X-100 (S2), then n-octyl-β-d-glucopyranoside (S3). The supernatants and insoluble pellet (P) were analyzed by IB with the indicated antibodies. T, total 
extract (starting material for the fractionation).
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and subjected to IB analysis. The protein levels of 14 known secre-
tory machinery components were examined; other than STXBP5, 
none appeared to be significantly altered (Figure 4A). To under-
stand the role of STXBP5, we examined stimulation-dependent 
release of cargo from all 3 platelet granules: dense granules, α 
granules, and lysosomes. Secretion of granule cargo from Stxbp5 
KO and WT platelets showed the expected thrombin dose depen-
dence (Figure 4B); however, the percentage release from α gran-
ules and lysosome was significantly affected by the loss of STXBP5. 
The release from dense granules was significantly affected, but to 
a lesser extent, in this assay system. The kinetics of secretion from 
with this area representing the centralized granulomere of an 
activated platelet. Immunofluorescence staining of STXBP5 in 
resting platelets, with circumferential tubulin rings, did not show 
any obvious colocalization with markers for the 3 specific platelet 
granule types (Figure 3, E–P).
STXBP5 is important for platelet secretion. To explore the func-
tional role of STXBP5, we analyzed Stxbp5 KO mice. As might be 
predicted from GWAS analysis (14–19), plasma vWF levels were 
increased in these mice, although plasma IgG was unaffected, as 
indicated by light chain levels (Supplemental Figure 1). Platelet 
extracts from Stxbp5 KO and littermate WT mice were prepared 
Figure 3. STXBP5 is present in platelets. Washed 
human platelets were allowed to bind to fibrinogen-
coated coverslip for 1 h at 37°C. After washing away 
the unbound platelets, the bound platelets were fixed 
and immunostained for STXBP5 (A), P-selectin (B) and 
F-actin using TRITC-phalloidin (C). Platelets were addi-
tionally stained with anti-STXBP5 antibodies (E, I, and 
M), anti-tubulin antibodies (G, K, and O) and antibod-
ies against markers for α granules (vWF; F), lysosomes 
(LAMP-1; J), and dense granules (CD63; N). Images in  
A–D were taken using a Zeiss LSM 780 confocal micro-
scope and processed using ZEN blue software, and 
images in E–P were taken using a Nikon A1R confocal 
microscope and processed using NIS-Elements AR 3.2 
software; D, H, L, and P show 3-color merged views. 
Scale bars: 10 μm (A–D); 1 μm (A–D, insets, and E–P).
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decrease in platelet factor 4 (PF4) in Stxbp5 KO versus WT platelets 
(Table 1). Serotonin and β-hexosaminidase levels were not signifi-
cantly reduced; in fact, total serotonin levels and uptake of [3H]-
serotonin were increased by approximately 60% (Table 1). These 
data suggest that STXBP5 contributes to granule biogenesis as well 
as to secretion. To characterize the effect of STXBP5 loss on plate-
let cargo, we probed extracts with granule-specific antibodies (Fig-
ure 7, A and B). IB data confirmed the reduction of PF4 and showed 
reduced levels of factor V. Platelet fibrinogen and vWF levels were 
modestly affected. The total levels of granule membrane proteins 
(e.g., LAMP-1 and P-selectin) were only slightly affected, while the 
surface expression of several platelet markers (e.g., GP1bβ, GPVI, 
and PECAM-1) was largely unaffected (Figure 7, B and C). Consis-
tent with the levels of LAMP-1 and P-selectin, EM analysis showed 
no significant difference in the number of granules present per 
platelet section when dense and α granules were counted (Table 1). 
These data argue that granules are made, but may not be normally 
loaded with cargo. Further analysis of soluble cargo levels yielded 
a complex phenotype. Antibody array analysis showed that several 
cargo proteins were reduced in Stxbp5 KO platelets. Others were 
unchanged, and a few, including MMP-9, showed robust increases 
(Figure 7D). All cargo proteins tested were detectable at some level 
(Supplemental Figure 4). These data indicate that STXBP5 contrib-
utes to the efficacy — and perhaps the selectivity — of granule cargo 
packaging, but is not essential for the process.
STXBP5 is important for hemostasis. The primary function of 
platelet secretion is in hemostasis. To assess whether STXBP5 
contributes to hemostasis, we used 2 in vivo assays. First, a tail 
bleeding time assay was performed on 5- to 6-week-old mice. 
Whereas the 19 WT littermates showed an average bleeding time 
of 226.4 ± 37.3 s, of the 24 Stxbp5 KO mice, only 3 had normal 
bleeding times; the remainder bled excessively until the study 
was ended at 10 minutes (Figure 8A). The prolonged tail bleed-
Stxbp5 KO platelets was also significantly defective upon activa-
tion with 0.1 U/ml thrombin (Figure 4C).
Because dense granule release is such a rapid process, measur-
ing [3H]-serotonin release in our assay configuration at room tem-
perature (Figure 4, B and C) may not be sufficient to fully appre-
ciate a subtle, albeit significant, kinetic defect. To rectify this, we 
applied more sensitive lumi-aggregometry to analyze ATP/ADP 
release from dense granules. ATP/ADP release in response to 
100 μM PAR-4, 10 nM A23187, 0.1 μg/ml convulxin, and 0.025, 
0.05, and 0.1 U/ml thrombin was substantially inhibited, whereas 
aggregation was not (Figure 5). Quantification of ATP/ADP release 
from 3 independent experiments showed significant reductions in 
Stxbp5 KO platelets (Figure 5, D and K). To further confirm that 
STXBP5 is required for α granule and lysosome release, exposure 
of the respective markers P-selectin and LAMP-1 was analyzed 
by flow cytometry. Consistently, activation-dependent exposure 
of both granule membrane markers was reduced approximately 
2-fold in Stxbp5 KO versus WT platelets (Figure 6, A and B).
In agreement with the aggregation data, there was no sig-
nificant difference in PE-conjugated JonA staining (Figure 6C), 
which suggests that depletion of STXBP5 did not affect integrin 
αIIbβ3 activation (15, 44, 45). Electron microscopy (EM) analysis 
detected no overt morphology differences in Stxbp5 KO platelets 
(Supplemental Figure 2). Upon thrombin stimulation, there was 
similar filopodia formation in both WT and Stxbp5 KO platelets, 
which suggests that deficiency of STXBP5 did not affect platelet 
cytoskeletal rearrangements or platelet activation, but did affect 
secretion. Additionally, adhesion to fibrinogen was not affected in 
Stxbp5 KO platelets, although there was a clear defect in spreading 
on fibrinogen (Supplemental Figure 3). This is consistent with the 
role of granule secretion in platelet spreading (46).
STXBP5 is important for platelet granule cargo packaging. As we 
measured cargo release as a percentage of total, we also detected a 
Figure 4. STXBP5-deficient mouse platelets 
have a secretion defect. (A) Platelet extracts 
(5 × 107 platelets/lane) were prepared from 
Stxbp5 KO and WT mice, and the indicated 
proteins were analyzed by IB. (B and C) [3H]-
Serotonin–labeled platelets from Stxbp5 KO 
and WT mice were prepared as described 
in Methods. Release of [3H]-serotonin from 
dense granules, PF4 from α granules, and 
β-hexosaminidase from lysosomes was mea-
sured, and percent secretion was calculated. 
(B) Thrombin dose-response experiment; 
platelets were stimulated for 1 minute. (C) 
Secretion time-course experiment; platelets 
were stimulated with 0.1 U/ml thrombin. 
Data are mean ± SEM of triplicate measure-
ments. Significant P values (2-way ANOVA) 
are indicated.
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ing of the Stxbp5 KO mice indicates that STXBP5 is required for 
hemostasis in this transection injury model.
In agreement with the tail bleeding, there was a robust throm-
bus formation defect observed in Stxbp5 KO mice in response 
to FeCl3 injury of the carotid artery. The average time required 
to form a stable thrombus in WT littermates was 2.7 ± 0.2 
minutes, in contrast to 27.7 ± 2.3 minutes for Stxbp5 KO mice 
(Figure 8B), which indicates that STXBP5 is critical for hemosta-
sis in this arterial injury model.
Platelet counts were not significantly different in Stxbp5 
KO and WT littermate mice, although the former exhibited an 
increase in mean platelet volume (Table 1); therefore, throm-
bocytopenia is unlikely to be the cause of the bleeding diathe-
sis. The combination of cargo and secretion deficiencies in the 
Stxbp5 KO platelets could account for the robust bleeding, but 
since the mouse strain is a global deletion, other processes could 
precipitate the hemostatic defects. To address whether the loss 
of STXBP5 in BM-derived platelets accounted for the hemo-
static defect, BM chimeras were constructed via transplantation: 
Stxbp5 KO BM was grafted into WT recipients, and vice versa. 
When Stxbp5 KO BM was grafted into WT recipients, there was 
a significant increase in bleeding times in the resulting chimeras 
compared with WT BM grafted into Stxbp5 KO recipients (Figure 
8C). Similarly, occlusion times in the carotid injury model were 
significantly prolonged in Stxbp5 KO BM–grafted WT chimeric 
mice (Figure 8D). These results suggest that loss of STXBP5 in 
BM-derived hematopoietic cells (e.g., platelets) contributes to 
the robust bleeding defect observed (Figure 8, A and B). Since the 
Stxbp5 KO animals grafted with WT BM had a normal bleeding 
profile, it seems unlikely that loss of STXBP5 affects coagulation 
factors, although this was not directly measured. In summary, 
these results indicate a role for STXBP5 in platelet granule pack-
aging and secretion and in arterial hemostasis.
Discussion
The novel findings herein were that STXBP5 was required for nor-
mal platelet secretion, granule cargo packaging, and hemostasis. 
This requirement of STXBP5 for platelet exocytosis diverges from 
the protein’s proposed role as a negative regulator in neuronal cell, 
neuroendocrine cell, and EC secretion (21, 24, 39, 47). Our pres-
ent data indicate that STXBP5 may be important for cardiovascu-
lar health, as echoed in recent GWAS in which STXBP5 has been 
linked to thrombosis (14–20).
Platelet granule release requires the secretory machinery 
components that are universally used for regulated secretion: 
SNAREs, Munc18, Rabs, and Munc13 (48). Much of the pub-
lished data suggest that STXBP5 is a negative regulator of secre-
tion, competing with v-SNAREs for t-SNARE binding. As in 
those prior studies, we showed here that STXBP5 interacted with 
t-SNARE–containing complexes and that its presence was exclu-
sive of at least 2 platelet v-SNAREs (Figure 2). However, deletion 
of STXBP5, as well as inclusion of an anti-STXBP5 antibody into 
Figure 5. Depletion of STXBP5 in platelets 
affects ATP/ADP release, but not aggrega-
tion. Aggregation (A–C and H–J) and ATP/
ADP release (D–G and K–N) were moni-
tored simultaneously in a lumi-aggregom-
eter. Washed platelets (2.0 × 105/μl) from 
Stxbp5 KO and WT mice were stimulated 
with 100 μM PAR-4 peptide (A and E), 10 
nM A23187 (B and F), 0.1 μg/ml convulxin 
(C and G), or thrombin (Thr) at 0.025 U/ml 
(H and M), 0.05 U/ml (I and N), or 0.1 U/ml 
(J and O) for 3 minutes. (A–C, E–J, and L–N) 
Representative traces from 1 experiment. 
(D and K) Mean ± SEM ATP/ADP release 
from 3 independent experiments.  
*P < 0.01, 2-way ANOVA.
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a permeabilized platelet secretion assay, inhibited rather than 
enhanced platelet secretion (Figures 4–6 and Supplemental Fig-
ure 5). This result raises the question of how STXBP5 could have a 
positive effect on exocytosis. Studies in Drosophila show that loss 
of STXBP5 prolongs the excitatory junctional currents (EJCs) at 
neuromuscular junctions (NMJs) (49). This could be due to ecto-
pic vesicle priming (adjacent to active zones) or prolonged fusion 
pore opening, which suggests that the role of STXBP5 is to spatial-
ly restrict vesicle priming and/or fusion. In platelets, spatial gran-
ule priming for exocytosis may be critical for efficacious secre-
tion. While our in-suspension secretion assays (Figures 4–6) may 
be less influenced by a loss of polarization, secretion in a form-
ing thrombus almost assuredly needs to be polarized (50). Thus, 
STXBP5 may be important for normal thrombosis, and its dele-
tion would cause the hemostasis defects we observed (Figure 8). 
At this stage, it is unclear why STXBP5 is important for secretion 
from yeast (25), INS-1E cells (35), or platelets (Figures 4–6); how-
ever, its interactions with cytoskeleton (Figure 2E and Figure 3), 
especially myosin Va (28, 42, 51), may hint at a role in spatially 
coordinating SNARE complexes for membrane fusion and sub-
sequent secretion. STXBP5 interactions with cytoskeleton could 
contribute to granule biogenesis by directing the trafficking of 
cargo proteins to α granules forming in megakaryocytes. The 
heterogeneity in cargo levels we observed herein (Figure 7 and 
Supplemental Figure 4) may be indicative of multiple pathways 
for granule cargo sorting and packaging. Further work will be 
required to address these potential functions of STXBP5.
GWAS have linked SNPs in STXBP5 to alterations in vWF 
levels (14–19) and tPA levels (18). Loss of STXBP5 increases vWF 
release from ECs (47), but decreases tPA release (20). These 
results highlight potentially conflicting roles for STXBP5 in ECs, 
which may relate to which granules are being released. vWF and 
tPA are enriched in different granules in ECs (52). Combining 
these 2 effects, heightened vWF and decreased tPA, might be 
expected to increase thrombotic risk, consistent with the premise 
of the GWAS. Conversely, an SNP encoding a nonsynonymous 
substitution in STXBP5 (N436S) has been linked to increased 
bleeding in a female population homozygous for the allele (18). 
The dramatically prolonged bleeding times in the tail transection 
model and the hemostasis defects in the FeCl3-induced carotid 
artery injury model we observed in Stxbp5 KO mice and in Stxbp5 
KO BM–grafted WT mice are consistent with this prior report and 
support a connection between STXBP5 and bleeding risk. At this 
Figure 6. Deletion of STXBP5 inhibits P-selectin 
and LAMP-1 exposure, but not integrin activa-
tion. Washed platelets (2 × 106) from Stxbp5 KO 
and WT mice were stimulated with or without 
0.1 U/ml thrombin for 1 minute and then incu-
bated with FITC-conjugated anti–P-selectin (A), 
FITC-conjugated LAMP-1 (B), or PE-conjugated 
JonA (C) Abs for 15 minutes at room tempera-
ture. Fluorescence intensities were measured 
by flow cytometry. Shown are representative 
data (black lines, resting; gray lines, stimulated) 
and geometric MFI (mean ± SEM) of 3 indepen-
dent experiments. Significant P values (2-way 
ANOVA) are indicated.
Table 1. Properties of WT and Stxbp5 KO mouse platelets
WT Stxbp5 KO P
Platelet count (×1,000/μl) 824 ± 123 881 ± 101 0.561
Mean platelet volume (fl) 4.20 ± 0.23 6.28 ± 0.10 0.001
Serotonin (μM/108 platelets)A 6.31 ± 0.5 10.64 ± 1.4 0.006
3[H]-Serotonin uptake (cpm/108 platelets) 2,515 ± 224 4,101 ± 545 0.036
PF4 (pg/106 platelets) 1,690 ± 120 545.5 ± 15 <0.0001
β-Hexosaminidase (nMh–1/106 platelets) 54 ± 10 57 ± 11 0.878
Dense granules/plateletB 0.46 ± 0.57 0.52 ± 0.57 0.320
α Granules/plateletB 7.97 ± 1.80 7.84 ±1.22 0.453
P values were calculated using Student’s t test. ADetermined using the 
fluorescence o-phthalaldehyde assay (see Supplemental Methods). 
BGranules in each platelet in an EM section were counted (n = 200 platelets 
counted).
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In summary, our data provide a potential explanation for the 
GWAS (14–19) linking STXBP5 with cardiovascular disease risk. 
Our findings showed that STXBP5 was present in platelets and was 
important for cargo release from dense granules, α granules, and 
lysosomes as well as for packaging of some cargo into granules. 
Mice with platelets deficient in STXBP5 displayed robust defects 
in thrombus formation in 2 arterial hemostasis models, consis-
tent with the granule biogenesis and release defects. Our data 
add another component to the pathway of protein-protein interac-
tions that culminates in platelet secretion. They also suggest that 
platelets may be a useful system for understanding how STXBP5 
positively affects exocytosis in other systems, perhaps through its 
associations with cytoskeleton. Moreover, platelet STXBP5 may 
be a useful diagnostic marker for cardiovascular diseases.
stage, it is unclear whether the N436S substitution has any effect 
on STXBP5 stability or function.
Zhu et al. have shown that loss of STXBP5 enhances EC secre-
tion of vWF and increases platelet binding to activated ECs (47). 
Consistent with our results (Supplemental Figure 1), Zhu et al. 
showed significantly increased plasma vWF levels in Stxbp5 KO 
mice (47). Clearly, the increased vWF is not sufficient to offset the 
platelet secretion defect described herein, since we observed bleed-
ing tendencies in the 2 arterial hemostasis models tested (Figure 8). 
However, venous thrombi are mainly composed of fibrin and red 
blood cells, whereas arterial thrombi are dominated by platelets 
and fibrin; therefore, it is possible that STXBP5-mediated platelet 
secretion is more important for arterial hemostasis. It remains to be 
determined how the loss of STXBP5 affects venous thrombosis.
Figure 7. STXBP5-deficient mouse platelets have a complex granule cargo defect. (A and B) Platelet extracts (5 × 107 platelets/lane) were prepared 
from 3 individual Stxbp5 KO or WT mice. The indicated proteins were analyzed by IB (A) and quantified with Image Lab 4.0.1 or ImageQuant TL. After 
normalization using RabGDI as loading control, the Stxbp5 KO/WT ratio was calculated (B). (C) Washed platelets (2 × 106) from 3 individual Stxbp5 KO or 
WT mice were incubated with FITC-conjugated anti-GP1bβ, anti-αIIbβ3, anti-GPVI, or anti–PECAM-1 for 15 minutes at room temperature. Geometric MFI 
(mean ± SEM) was determined using flow cytometry. (D) Antibody array analysis of platelet extracts. Extracts were prepared from WT or Stxbp5 KO mice 
and probed using duplicate Proteome Profiler Mouse Angiogenesis Antibody Arrays (see Methods). The fluorescence intensity from 2 experiments was 
used to calculate a Stxbp5 KO/WT ratio for each protein detected on the array. The average of the 2 calculated ratios is plotted. Note that the y axis is a 
log scale. SDF-1, PF4, and angiopoietin 1 were excluded from analysis due to saturation of their respective spots on the array membranes.
Downloaded October 17, 2014 from The Journal of Clinical Investigation. doi:10.1172/JCI75572.
The Journal of Clinical Investigation   R e s e a R c h  a R t i c l e
4 5 2 5jci.org   Volume 124   Number 10   October 2014
specific for the b-STXBP5 (5′-CTCCGACTTCCGGTTCTTCCTC-3′ 
and 5′-TTCAGCGTGATGACAAAGGC-3′), m-STXBP5 (5′-CTCCG-
ACTTCCGCAAAGATGTC-3′ and 5′-TTCAGCGTGATGACAAAG-
GC-3′), and s-STXBP5 (5′-CTCCGACTTCCGATGTGAAAG-3′ and 
5′-TTCAGCGTGATGACAAAGGC-3′) isoforms (29, 40).
Immunoprecipitation of STXBP5-interacting proteins. Washed 
platelet suspensions (109 platelets) were lysed with equal volumes 
of 2× lysis buffer (100 mM HEPES/KOH, pH 7.4; 2% Triton X-100; 
2 mM EGTA; 2 mM EDTA; 150 mM NaCl; and 2× protease inhibitor 
cocktail) on ice for 30 minutes. The lysates were clarified by cen-
trifugation, and the supernatants were precleared with protein G/A 
sepharose (GE Healthcare). The interacting proteins were immuno-
precipitated with anti-STXBP5, anti-Munc18b, or anti–Munc13-4 Abs, 
followed by incubation with protein G sepharose. The immunoprecip-
itates were recovered by centrifugation, washed with lysis buffer, and 
analyzed by SDS-PAGE and IB.
Genotyping of Stxbp5 KO mice. Stxbp5 KO mice on a 50% 129Sv, 25% 
C57BL/6, and 25% DBA/2 background were generated as previously 
described (32). Heterozygous embryos of Stxbp5 KO mice were recov-
ered into live mice by the Jackson Laboratory. Genotype was determined 
by PCR using DNA isolated from tail tip biopsies. The primers used were 
as follows: Stxbp5 KO forward, 5′-GGGCGCCCGGTTCTTTTTGTC-3′; 
Stxbp5 KO reverse, 5′-GCCATGATGGATACTTTCTCG-3′; WT for-
ward, 5′-TTCTGCTCCCCGCTGCTCCTT-3′; WT reverse, 5′-TCCCC-
GCTCCCTTCACCTTGC-3′. PCR products were 224 bp for the Stxbp5 
KO allele and 300 bp for the WT allele.
Measurement of secretion from intact platelets. The secretion assay 
was carried out as described previously (13); see Supplemental Meth-
ods for details. Briefly, washed platelets were labeled with [3H]-sero-
tonin (0.4 μCi/ml) for 1 hour at 37°C. After washing with HEPES/
Tyrode buffer (10 mM HEPES/NaOH, pH 7.4; 5.56 mM glucose; 
137 mM NaCl; 12 mM NaHCO3; 2.7 mM KCl; 0.36 mM KH2PO4; and 
1 mM MgCl2) in the presence of 0.2 U/ml apyrase, the platelets were 
resuspended and adjusted to 2.5 × 105/μl. For titration experiments, 
the indicated concentrations of thrombin were added, and the reac-
tions were stopped at 1 minute with a 2-fold excess of hirudin. For 
time course experiments, 0.1 U/ml thrombin was added for the 
indicated times, and reactions were stopped with hirudin. Superna-
tants and pellets were recovered after centrifugation at 13,000 g for 
Methods
Antibodies and reagents. Anti-STXBP5 mAb (611296), anti-Rab27a mAb 
(clone 20.1), anti-PECAM, FITC-conjugated anti-mouse P-selectin, 
and unconjugated anti-mouse P-selectin were from BD Biosciences. A 
rabbit anti-STXBP5 polyclonal Ab (HPA039991) was from Atlas Anti-
bodies. The anti–hLAMP-1 (H4A3) and anti-hCD63 (H5C6) mAbs were 
from the University of Iowa Developmental Studies Hybridoma Bank. 
Anti-Munc18b (sc-14563) polyclonal Ab was from Santa Cruz. Anti-
bodies against STX2, STX4, STX7, SNAP23, VAMP8, Munc18c, Rab-
GDI, VAMP2 (synaptobrevin), VAMP3 (cellubrevin), VAMP7, VAMP8 
(endobrevin), and Munc13-4 were as described previously (6, 8, 53). 
Anti-STX11 polyclonal Ab and anti-Munc18a mAb (clone 131.1) were 
purchased from Synaptic System GmbH. PE-conjugated JonA mAb, 
anti-GP1bβ, and anti GPVI Abs were purchased from Emfret Analytics. 
Anti-human fibrinogen and anti-vWF polyclonal Abs were from Dako. 
The anti–integrin β3 antibody and the Alexa Fluor 647–labeled rabbit 
anti–α-tubulin antibody (11H10) were from Cell Signaling. The anti–
factor V antibody was provided by B. Bouchard (University of Vermont, 
Burlington, Vermont, USA). A STXBP5 expression vector (provided by 
U. Ashery, Tel Aviv University, Tel Aviv, Israel) was used to make anti-
gens for the production and purification of a polyclonal anti-STXBP5 
antibody (see Supplemental Methods). Anti–β-actin antibody and 
alkaline phosphatase–conjugated anti-IgGs were from Sigma-Aldrich. 
Protein A–conjugated sepharose, 2-methyl-2-butanol, 2,2,2 tribromo-
ethanol (Avertin), and FeCl3 were from Sigma-Aldrich. The rest of the 
materials used in this study were of reagent grade.
Protein production. Expression plasmids to create complexes of 
full-length human SNAP23, Munc18a, and Munc18c and the cyto-
plasmic domains of human STX2 (aa 1–251) and STX4 (aa 1–265) 
were constructed using pRSFDuet-1 (Novagen) and confirmed by 
DNA sequencing. All syntaxin-containing complexes were expressed 
in E. coli and purified using Ni2+-NTA (6) and S-protein (Novagen) 
affinity chromatography.
RT-PCR. Identification of STXBP5 isoforms was performed as 
described previously (29, 40), with slight modification. Human plate-
lets were isolated from banked, platelet-rich plasma (13), total RNA 
was isolated using QIAamp RNA Blood Mini Kit (QIAGEN), and cDNA 
was synthesized using TaqMan Reverse Transcription Reagents Kit 
(Applied Biosystems). PCR amplification was performed using primers 
Figure 8. Hemostasis and thrombus formation are impaired in 
STXBP5-deficient mice. (A) Tail bleeding times were measured 
after tail transection from Stxbp5 KO (n = 24) and WT (n = 19) litter-
mates. (B) Thrombus formation in the carotid artery was induced 
by topical application of 5% FeCl3, and blood flow was monitored 
from Stxbp5 KO (n = 10) and WT (n = 9) littermates. (C and D) 
Chimeric mice (WT BM transplanted into Stxbp5 KO littermates 
[WT→KO], n = 7; Stxbp5 KO BM transplanted into WT littermates 
[KO→WT], n = 5) were analyzed using the same assays. Tail 
bleeding times (C) and the time to blood flow cessation from 5% 
FeCl3-induced carotid thrombosis (D) were measured. Each symbol 
represents an individual mouse; mean ± SEM are noted. P values 
(log-rank test) are indicated.
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Inc.) was placed on the artery to monitor blood flow. Thrombus for-
mation was induced by placing a small piece of filter paper, saturated 
with 5% FeCl3 solution, on the vessel for 3 minutes. Time from appli-
cation to cessation of flow was measured. Experiments were termi-
nated at 30 minutes. Statistical analysis was performed using the 
log-rank test (GraphPad Prism 5).
BM transplantation mouse model. BM transplantation was per-
formed as previously described (58), with some modification. Briefly, 
BM harvested from femurs and tibias of 6-week-old WT or Stxbp5 KO 
mice was resuspended with 10 mM HEPES, pH 7.4 buffer containing 
25 U/ml heparin and 5% FBS and adjusted to 5 × 107 cells/ml. The cell 
suspension (0.1 ml) was injected into the retroorbital sinus of lethally 
irradiated mice. After 6 weeks of recovery, tail bleeding and FeCl3-
induced hemostasis assays were performed. Statistical analysis was 
performed using the log-rank test (GraphPad Prism 5).
Subcellular fractionation of platelets. Human platelets were resus-
pended in HEPES/Tyrode buffer (pH 7.4) and treated with or without 
0.1 U/ml thrombin for 5 minutes. The resting and activated platelets 
were disrupted by 5 freeze-thaw cycles. After disruption, the unbroken 
cells were removed by centrifugation at 700 g for 5 minutes, and the 
supernatants were fractionated by ultracentrifugation at 100,000 g 
for 1 hour. The supernatant (cytosol) was collected, and the result-
ing pellets were solublized with 1% Triton X-100, incubated on ice 
for 15 minutes, and then subjected to centrifugation at 100,000 g 
for 1 hour. The supernatant (Triton X-100–soluble fraction) was col-
lected, and the resulting pellets were solublized with 1% n-octyl-β-d-
glucopyranoside, incubated on ice for 15 minutes, and then subjected 
to centrifugation at 100,000 g for 1 hour. The supernatant (n-octyl-
β-d-glucopyranoside–soluble fraction) was collected. The detergent-
insoluble pellets were solublized in SDS-PAGE loading buffer. The 
supernatants (soluble fractions) and pellets (detergent-insoluble frac-
tions) were probed by IB using anti-STXBP5, anti-RabGDI, anti-STX4, 
anti-SNAP23, and anti–β-actin antibodies.
Angiogenesis antibody array analysis of platelet granule cargo. Pro-
teome Profiler Mouse Angiogenesis Antibody Array (ARY 015; R&D 
Systems) was used according to the manufacturer’s instructions. 
Briefly, the nitrocellulose membranes were first incubated in blocking 
buffer for 1 hour. Platelet extracts (from 108 platelets) were prepared in 
1 ml lysis buffer (1% NP-40; 20 mM Tris-HCl, pH 8.0; 137 mM NaCl; 
10% glycerol; 2 mM EDTA; and 10× protease inhibitor cocktail) and 
mixed with a cocktail of biotin-labeled detection antibodies against 
different individual angiogenesis-related proteins. After incubation 
for 1 hour, the mixture of the platelet sample and detection antibod-
ies was then incubated with the nitrocellulose membranes O/N at 4°C. 
The membranes were washed 3 times and incubated with HRP-con-
jugated streptavidin for 30 minutes. After washing the membranes 3 
times, the signals for each array spot were detected with Supersignal 
ELISA Femto Maximum Sensitivity Substrate (Thermo-Scientific) 
using a ChemiDoc MP System (BioRad). The array experiments were 
run in duplicate. Fluorescence intensities for each spot were mea-
sured, background was subtracted, and the Stxbp5 KO/WT ratio was 
calculated and plotted using SigmaPlot (version 12.0; Systat Software 
Inc.). Under these conditions, spots for 3 proteins — SDF-1, PF4, and 
angiopoietin 1 — were saturated, and thus failed to yield quantitative 
data (Supplemental Figure 4). These were excluded from analysis.
Statistics. Data from bleeding time and occlusion assays were ana-
lyzed by log-rank test. Data from secretion assays and FACS-based 
1 minute, and the pellets were lysed with an equal volume of lysis 
buffer (PBS, pH 7.4, and 1% Triton X-100) for 1 hour on ice. Both 
supernatants and pellets were assayed for 3 granule cargo markers: 
[3H]-serotonin for dense granules by scintillation counting, platelet 
factor 4 (PF4) for α granules by ELISA, and β-hexosaminidase for 
lysosomes by colorimetric assay using p-nitrophenyl-N-acetyl-β- 
d-glucosaminide, as previously described (54). Secretion was then 
calculated as (supernatant/[supernatant + pellet]) and expressed as 
a percentage; the analysis yields a measurement of total cargo con-
tent (supernatant plus pellet) and allows for assessment of secretion 
efficacy independent of cargo content.
Immunofluorescence microscopy. Platelet preparation and immuno-
staining were performed as previously described (55), with slight 
modification. Briefly, sterile glass coverslips were coated with 50 
μg/ml human fibrinogen for 24 hours at 4°C. Washed platelets were 
placed onto fibrinogen-coated coverslips for 1 hour at 37°C. Platelets 
were fixed with 4% paraformaldehyde for 15 minutes and quenched 
with 50 mM NH4Cl. Cells were rinsed with 10% FBS/PBS and incu-
bated with the indicated primary antibodies in 10% FBS/PBS contain-
ing 0.2% saponin O/N at 4°C. After washing with 10% FBS/PBS, cells 
were incubated with the appropriate fluorophore-conjugated anti-IgG 
secondary antibody for 2 hours. After washing, some samples were 
incubated with TRITC-conjugated phalloidin in 10% FBS/PBS with 
0.2% saponin. Coverslips were mounted and examined with a LSM 
780 confocal microscope (Carl Zeiss), and images were processed 
using ZEN blue software (Carl Zeiss). Additional imaging was done 
using a Nikon A1R confocal microscope, and images were processed 
using NIS-Elements AR 3.2 software (Nikon).
Platelet aggregation and ATP/ADP release. Murine platelets (2.5 × 105/
μl) were prepared (13), recalcified with 0.7 mM CaCl2, placed into silicon-
ized cuvettes, and stirred for 3 minutes at 37°C at 1,200 rpm. Luciferin-
luciferase substrate was added, followed by the indicated agonists, and 
the percent change in light transmission was measured. Aggregation and 
ATP/ADP secretion were monitored using a Model 460VS Lumi-Dual-
aggregometer, and traces were acquired using a Model 810 Aggro/Link 
interface with Aggro/Link software (all from Chrono-Log).
Flow cytometry analysis. Washed murine platelets (2 × 106) were 
kept as resting or were stimulated with thrombin (0.1 U/ml) for 1 min-
ute, after which the reaction was stopped with hirudin. After incuba-
tion with antibodies (5 μl) for 15 minutes at room temperature, the 
reactions were diluted 10-fold with HEPES/Tyrode buffer (pH 6.5). 
The samples were transferred to tubes, and fluorescence intensities 
were measured using a FACScan flow cytometer and analyzed using 
CellQuest (BD Biosciences).
Tail bleeding assay. Tail vein bleeding times were determined as 
previously described (56). Briefly, 5- to 6-week-old mice were anes-
thetized with ketamine (75 mg/kg i.p.). Tails were transected 3 mm 
from the tip and immersed in saline at 37°C. The time from incision to 
bleeding cessation was recorded. Animals were observed for an addi-
tional minute to assess rebleeding. Prolonged bleeding was stopped 
manually after 10 minutes. Statistical analysis was performed using 
the log-rank test (GraphPad Prism 5).
FeCl3-induced arterial hemostasis model. The FeCl3-induced arte-
rial thromobosis model was as previously described (57). Briefly, 
mice 8–12 weeks of age were anesthetized with Avertin (0.2 g/kg 
i.p.) and placed on a 37°C heating pad. The left carotid artery was 
exposed, and a Doppler TS420 flowmeter (0.5VB; Transonic System 
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